Spots Global Cancer Trial Database for A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Official Title: A Phase Ib/II ,Single Arm, Multi-Center, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of JAB-21822 in Advanced or Metastatic Non-small Cell Lung Cancer With a KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Study ID: NCT05276726
Conditions
Interventions
Study Description
Brief Summary: Evaluate the safety and tolerability, drug levels, and clinical activity of JAB-21822 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors with KRAS p.G12C mutation and a serine/threonine kinase 11 (STK11) co-mutation.
Detailed Description: The primary objective of this study is to evaluate the safety and tolerability of JAB-21822 during Dose Escalation phase and preliminary antitumor activity in patients with NSCLC with concurrent KRAS G12C mutant and STK11 mutant and KEAP wild type either treatment naïve or at least one line prior therapy for advance disease during the expansion phase..
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research site08, Beijing, Beijing, China
Research site09, Beijing, Beijing, China
Research site021, Beijing, Beijing, China
Research site02, Beijing, Beijing, China
Research site01, Beijing, Beijing, China
Research site013, Beijing, Beijing, China
Research site010, Chongqing, Chongqing, China
Research site05, Xiamen, Fujian, China
Research site011, Shenzhen, Guangdong, China
Research site016, Nanning, Guangxi, China
Research site017, Shijiazhuang, Hebei, China
Research site018, Ha'erbin, Heilongjiang, China
Research site04, Zhengzhou, Henan, China
Research site012, Changsha, Hunan, China
Research site015, Changchun, Jilin, China
Research site06, Shenyang, Liaoning, China
Research site07, Shenyang, Liaoning, China
Research site014, Hohhot, Neimenggu, China
Research site020, Xi'an, Shanxi, China
Research site03, Hubei, Wuhan, China
Research site019, Hangzhou, Zhejiang, China
Contact Details
Name: Jacobio Pharmaceuticals
Affiliation: Jacobio Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
